Literature DB >> 9225278

Differential distribution of [3H]sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on brainstem and spinal cord.

M E Castro1, J Pascual, T Romón, C del Arco, E del Olmo, A Pazos.   

Abstract

We report on the autoradiographic distribution of 5-HT1B, 5-HT1D and 5-HT1F receptor subtypes in human brain, focusing on the brainstem and cervical spinal cord. We have used [3H]sumatriptan as a radioligand in the presence of suitable concentrations of 5-CT (5-carboxamidotryptamine) to define 5-HT1F receptors, and ketanserin, to discriminate between 5-HT1B and 5-HT1D receptors. In the brainstem the highest concentrations of [3H]sumatriptan binding sites were seen in substantia nigra. The spinal trigeminal nucleus, substantia gelatinosa of the spinal cord, nucleus of the tractus solitarius and periaqueductal grey, also showed significant levels of [3H]sumatriptan binding sites. In the brainstem and spinal cord the total population of 5-CT-insensitive receptors, corresponding to 5-HT1F receptors, ranged from 9.8% in the periaqueductal grey to 53.4% in the substantia gelatinosa. This population represented 67.0% of binding in layer V of the frontal cortex. The decrease in [3H]sumatriptan binding in the presence of 200 nM ketanserin, indicative of the presence of 5-HT1D receptors, was very limited throughout the human brain, only reaching 20% of total specific binding over the periaqueductal grey. The proportion of [3H]sumatriptan binding sites displaced by 5-CT and insensitive to ketanserin, corresponding to 5-HT1B receptors, was, in general, the most abundant, ranging from 43.8% in substantia gelatinosa to 69.9% in the periaqueductal grey. Significant levels of 5-HT1B and 5-HT1D receptors found in migraine control pain areas suggest their involvement in antinociceptive mechanisms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9225278     DOI: 10.1016/s0028-3908(97)00061-0

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  19 in total

1.  [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain.

Authors:  Virginia L Lucaites; Joseph H Krushinski; John M Schaus; James E Audia; David L Nelson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-04-27       Impact factor: 3.000

2.  5-hydroxytryptamine 1F Receptor Agonist Induces Mitochondrial Biogenesis and Promotes Recovery from Spinal Cord Injury.

Authors:  Epiphani C Simmons; Natalie E Scholpa; Kristan H Cleveland; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2019-11-27       Impact factor: 4.030

3.  [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties.

Authors:  David B Wainscott; Joseph H Krushinski; James E Audia; John M Schaus; John M Zgombick; Virginia L Lucaites; David L Nelson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-04-27       Impact factor: 3.000

Review 4.  Preclinical neuropharmacology of naratriptan.

Authors:  Geoffrey A Lambert
Journal:  CNS Drug Rev       Date:  2005

5.  Activation of 5-HT1B and 5-HT1D receptors in the rat nucleus tractus solitarius: opposing action on neurones that receive an excitatory vagal C-fibre afferent input.

Authors:  R D Jeggo; Y Wang; D Jordan; A G Ramage
Journal:  Br J Pharmacol       Date:  2007-03-05       Impact factor: 8.739

Review 6.  Mitochondrial biogenesis as a therapeutic target for traumatic and neurodegenerative CNS diseases.

Authors:  Epiphani C Simmons; Natalie E Scholpa; Rick G Schnellmann
Journal:  Exp Neurol       Date:  2020-04-11       Impact factor: 5.330

Review 7.  Does sumatriptan cross the blood-brain barrier in animals and man?

Authors:  Peer Carsten Tfelt-Hansen
Journal:  J Headache Pain       Date:  2009-12-10       Impact factor: 7.277

8.  Reversal of inflammatory and noninflammatory visceral pain by central or peripheral actions of sumatriptan.

Authors:  Louis P Vera-Portocarrero; Michael H Ossipov; Tamara King; Frank Porreca
Journal:  Gastroenterology       Date:  2008-07-03       Impact factor: 22.682

9.  5-HT1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson's disease.

Authors:  Natalie E Scholpa; Mary K Lynn; Daniel Corum; Heather A Boger; Rick G Schnellmann
Journal:  Br J Pharmacol       Date:  2017-12-22       Impact factor: 8.739

Review 10.  Future drugs for migraine.

Authors:  Ivano Farinelli; Sergio De Filippis; Gabriella Coloprisco; Serena Missori; Paolo Martelletti
Journal:  Intern Emerg Med       Date:  2009-06-24       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.